Contact | Print version | PDF version | Send article | RSS feed

Sosei announces progression of SD118 for the treatment of neuropathic pain towards Phase 1 studies

26 Feb 2007 - Sosei Group Corporation announced that its collaborative project SD118, which is under development for the treatment of neuropathic pain, has successfully completed regulatory pre-clinical studies and will now be progressed into Phase 1 clinical trials.
 
SD118 is being jointly developed with NeuroDiscovery Ltd and its wholly owned subsidiary NeuroSolutions Ltd under a Collaboration Agreement concluded in June 2006. SD118 was previously under investigation in Japan for a different indication and now, following re-profiling, has demonstrated its potential as a new oral neuropathic pain therapy.
 
Sosei will shortly make a Clinical Trial Application in the UK to facilitate the Phase 1 trials commencement.